Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donidalorsen - Ionis Pharmaceuticals

Next Previous
Drug Profile

Donidalorsen - Ionis Pharmaceuticals

Alternative Names: Donidalorsen sodium; IONIS-PKK-L Rx; ISIS 721744

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Anti-inflammatories; Antisense oligonucleotides; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hereditary angioedema
  • Phase II COVID 2019 infections

Most Recent Events

  • 01 Apr 2024 Updated efficacy and adverse event data from a phase II trial in Hereditary angioedema presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
  • 23 Feb 2024 Efficacy and adverse event data from the phase II extension trial in Hereditary angioedema presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology 2024 (AAAAI-2024)
  • 19 Feb 2024 Donidalorsen - Ionis Pharmaceuticals receives Orphan Drug status for Hereditary angioedema in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top